Corrigendum: Factors influencing delayed clearance of high dose methotrexate (HDMTX) in pediatric, adolescent, and young adult oncology patients (Frontiers in Oncology, (2023), 13, (1280587), 10.3389/fonc.2023.1280587)

Ema Mosleh; Stacy Snyder; Ningying Wu; Daniel N. Willis; Rema Malone; Robert J. Hayashi

doi:10.3389/fonc.2023.1333273

Corrigendum: Factors influencing delayed clearance of high dose methotrexate (HDMTX) in pediatric, adolescent, and young adult oncology patients (Frontiers in Oncology, (2023), 13, (1280587), 10.3389/fonc.2023.1280587)

Ema Mosleh
, Stacy Snyder
, Ningying Wu
, Daniel N. Willis
, Rema Malone
, Robert J. Hayashi

Research output: Contribution to journal › Comment/debate

Abstract

In the original article, there was an error in the author list order, as published. Instead of “Ema Mosleh^1*, Stacy Snyder^1†, Ningying Wu², Daniel N. Willis¹, Robert J. Hayashi¹, Rema Malone³”, It should be “Ema Mosleh^1*, Stacy Snyder^1†, Ningying Wu², Daniel N. Willis¹, Rema Malone³, Robert J. Hayashi¹”. The authors apologize for these errors and state that they do not change the scientific conclusions of the article in any way. The original article has been updated.

Original language	English
Article number	1333273
Journal	Frontiers in Oncology
Volume	13
DOIs	https://doi.org/10.3389/fonc.2023.1333273
State	Published - 2023

Keywords

adverse effect
AYA
delayed clearance
HDMTX
methotrexate
nephrotoxicity
pediatric cancer
supportive care

Access to Document

10.3389/fonc.2023.1333273

Fingerprint

Dive into the research topics of 'Corrigendum: Factors influencing delayed clearance of high dose methotrexate (HDMTX) in pediatric, adolescent, and young adult oncology patients (Frontiers in Oncology, (2023), 13, (1280587), 10.3389/fonc.2023.1280587)'. Together they form a unique fingerprint.

Cite this

Mosleh, E., Snyder, S., Wu, N., Willis, D. N., Malone, R., & Hayashi, R. J. (2023). Corrigendum: Factors influencing delayed clearance of high dose methotrexate (HDMTX) in pediatric, adolescent, and young adult oncology patients (Frontiers in Oncology, (2023), 13, (1280587), 10.3389/fonc.2023.1280587). Frontiers in Oncology, 13, Article 1333273. https://doi.org/10.3389/fonc.2023.1333273

@article{0047bd88ab564a04b5150b50e135e608,

title = "Corrigendum: Factors influencing delayed clearance of high dose methotrexate (HDMTX) in pediatric, adolescent, and young adult oncology patients (Frontiers in Oncology, (2023), 13, (1280587), 10.3389/fonc.2023.1280587)",

abstract = "In the original article, there was an error in the author list order, as published. Instead of {\textquotedblleft}Ema Mosleh1*, Stacy Snyder1†, Ningying Wu2, Daniel N. Willis1, Robert J. Hayashi1, Rema Malone3{\textquotedblright}, It should be {\textquotedblleft}Ema Mosleh1*, Stacy Snyder1†, Ningying Wu2, Daniel N. Willis1, Rema Malone3, Robert J. Hayashi1{\textquotedblright}. The authors apologize for these errors and state that they do not change the scientific conclusions of the article in any way. The original article has been updated.",

keywords = "adverse effect, AYA, delayed clearance, HDMTX, methotrexate, nephrotoxicity, pediatric cancer, supportive care",

author = "Ema Mosleh and Stacy Snyder and Ningying Wu and Willis, \{Daniel N.\} and Rema Malone and Hayashi, \{Robert J.\}",

note = "Publisher Copyright: Copyright {\textcopyright} 2023 Mosleh, Snyder, Wu, Willis, Malone and Hayashi.",

year = "2023",

doi = "10.3389/fonc.2023.1333273",

language = "English",

volume = "13",

journal = "Frontiers in Oncology",

issn = "2234-943X",

}

Mosleh, E, Snyder, S, Wu, N, Willis, DN, Malone, R & Hayashi, RJ 2023, 'Corrigendum: Factors influencing delayed clearance of high dose methotrexate (HDMTX) in pediatric, adolescent, and young adult oncology patients (Frontiers in Oncology, (2023), 13, (1280587), 10.3389/fonc.2023.1280587)', Frontiers in Oncology, vol. 13, 1333273. https://doi.org/10.3389/fonc.2023.1333273

Corrigendum: Factors influencing delayed clearance of high dose methotrexate (HDMTX) in pediatric, adolescent, and young adult oncology patients (Frontiers in Oncology, (2023), 13, (1280587), 10.3389/fonc.2023.1280587). / Mosleh, Ema; Snyder, Stacy; Wu, Ningying et al.
In: Frontiers in Oncology, Vol. 13, 1333273, 2023.

Research output: Contribution to journal › Comment/debate

TY - JOUR

T1 - Corrigendum

T2 - Factors influencing delayed clearance of high dose methotrexate (HDMTX) in pediatric, adolescent, and young adult oncology patients (Frontiers in Oncology, (2023), 13, (1280587), 10.3389/fonc.2023.1280587)

AU - Mosleh, Ema

AU - Snyder, Stacy

AU - Wu, Ningying

AU - Willis, Daniel N.

AU - Malone, Rema

AU - Hayashi, Robert J.

PY - 2023

Y1 - 2023

N2 - In the original article, there was an error in the author list order, as published. Instead of “Ema Mosleh1*, Stacy Snyder1†, Ningying Wu2, Daniel N. Willis1, Robert J. Hayashi1, Rema Malone3”, It should be “Ema Mosleh1*, Stacy Snyder1†, Ningying Wu2, Daniel N. Willis1, Rema Malone3, Robert J. Hayashi1”. The authors apologize for these errors and state that they do not change the scientific conclusions of the article in any way. The original article has been updated.

AB - In the original article, there was an error in the author list order, as published. Instead of “Ema Mosleh1*, Stacy Snyder1†, Ningying Wu2, Daniel N. Willis1, Robert J. Hayashi1, Rema Malone3”, It should be “Ema Mosleh1*, Stacy Snyder1†, Ningying Wu2, Daniel N. Willis1, Rema Malone3, Robert J. Hayashi1”. The authors apologize for these errors and state that they do not change the scientific conclusions of the article in any way. The original article has been updated.

KW - adverse effect

KW - AYA

KW - delayed clearance

KW - HDMTX

KW - methotrexate

KW - nephrotoxicity

KW - pediatric cancer

KW - supportive care

UR - https://www.scopus.com/pages/publications/85179179912

U2 - 10.3389/fonc.2023.1333273

DO - 10.3389/fonc.2023.1333273

M3 - Comment/debate

C2 - 38090499

AN - SCOPUS:85179179912

SN - 2234-943X

VL - 13

JO - Frontiers in Oncology

JF - Frontiers in Oncology

M1 - 1333273

ER -

Corrigendum: Factors influencing delayed clearance of high dose methotrexate (HDMTX) in pediatric, adolescent, and young adult oncology patients (Frontiers in Oncology, (2023), 13, (1280587), 10.3389/fonc.2023.1280587)

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this